Quarterly report pursuant to Section 13 or 15(d)

Equity

v3.7.0.1
Equity
3 Months Ended
Mar. 31, 2017
Equity [Abstract]  
Equity

Note 11 - Equity

 

The holders of common shares are entitled to one vote per share at meetings of the Company. Holders of Series A convertible preferred shares are entitled to five votes per share at meetings of the Company.

 

A restricted stock award is an award of common shares that are subject to certain restrictions during a specified period. Restricted stock awards are independent of option grants and are generally subject to forfeiture if employment terminates prior to the release of the restrictions. The grantee cannot transfer the shares before the restricted shares vest. Shares on non-vested restricted stock have the same voting rights as common stock, are entitled to receive dividends and other distributions thereon and are considered to be currently issued and outstanding. The Company’s restricted stock awards vest of a period of one to three years. The Company expenses the cost of the restricted stock awards, which is determined to be the fair market value of the shares at the date of grant, straight-line over the period during which the restrictions lapse. For these purposes, the fair market value of the restricted stock is determined based on the closing price of the Company’s common stock on the grant date.

 

On June 8, 2016, the Company issued 27,500 restricted common shares to an officer in connection with his employment agreement. These shares vest 1/3 immediately on the date of the grant and the remaining 2/3 vests equally on March 1, 2017 and March 1, 2018. The fair value of these shares was $54,725 and was based on the share price on the date of the grant. $5,204 was recorded during the three months ended March 31, 2017 as administrative expense on the Condensed Consolidated Statement of Operations and Comprehensive Loss and the remaining $19,369 is reported as deferred compensation, a contra equity account, on the Condensed Consolidated Balance Sheet as of March 31, 2017.

 

On January 13, 2017, the Company completed a public offering of 1,789,500 common shares, raising net proceeds of $1,692,044. Below is a summary of the gross proceeds to net proceeds calculation.

 

 

    Public Offering - January 13, 2017  
    Shares     $     $  
Common Shares                  
Base Offering     1,667,000       2,000,400          
Over-Allotment     122,500       147,000          
Gross Proceeds                     2,147,400  
Underwriter/Gunnar Expenses                        
Discount             150,318          
Legal Fees             60,000          
Roadshow             1,783          
Miscellaneous             34,005          
Total                     246,106  
Akers Biosciences Expenses                        
Legal & Accounting             197,813          
Registration/Regulatory             11,437          
Total                     209,250  
Net Proceeds                     1,692,044  

 

In addition to the common shares issued, the Company also issued 833,500 warrants with an exercise price of $1.50 per common share in support of the base offering and 61,250 warrants with an exercise price of $1.20 per common share. All of the warrants issued have a five-year term.

 

On March 27, 2017, two warrant holders from the January 13, 2017 public offering executed 160,000 warrants with an exercise price of $1.50 per common share, raising net proceeds of $240,000.

 

On March 28, 2017, two warrant holders from the January 13, 2017 public offering executed 3,300 warrants with an exercise price of $1.50 per common share, raising net proceeds of $4,950.

 

On March 30, 2017, the Company completed a private placement of 1,448,400 unregistered shares of common stock, raising net proceeds of $1,760,817. The unregistered shares will be admitted to trading once a Registration Statement, which will be filed with the Securities and Exchange Commission within 20 days, has been deemed effective. Below is a summary of the gross proceeds to net proceeds calculation.

 

    Private Placement - March 30, 2017  
    Shares     $     $  
Common Shares                  
 Base Offering     1,448,400       2,027,760          
Gross Proceeds                     2,027,760  
 Underwriter/Gunnar Expenses                        
  Discount             141,943          
  Legal Fees             50,000          
 Total                     191,943  
 Akers Biosciences Expenses                        
  Legal & Accounting             75,000          
 Total                     75,000  
Net Proceeds                     1,760,817  

 

In addition to the common shares issued, the Company also issued 724,200 warrants with an exercise price of $1.96 per common share with a five-year term. 

 

The following is a reconcilement of the movement of shares of Series A Convertible Preferred stock (“preferred stock”) and common stock:

 

    Authorized     Issued  
    Preferred     Common     Preferred     Common  
    Stock     Stock     Stock     Stock  
Balance at December 31, 2016     50,000,000       500,000,000       -       5,452,545  
                                 
Shares Issued:                                
  January 13, 2017     -       -       -       1,789,500  
  March 27, 2017     -       -       -       160,000  
  March 28, 2017     -       -       -       3,300  
  March 30, 2017     -       -       -       1,448,400  
Balance at March 31, 2017     50,000,000       500,000,000       -       8,853,745